ImStem Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- ImStem Biotechnology's estimated annual revenue is currently $3.3M per year.
- ImStem Biotechnology's estimated revenue per employee is $155,000
Employee Data
- ImStem Biotechnology has 21 Employees.
- ImStem Biotechnology grew their employee count by -9% last year.
ImStem Biotechnology's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO, ImStem | Reveal Email/Phone |
3 | VP / CTO/Founder | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Quality Assurance Officer | Reveal Email/Phone |
6 | Executive Administrator/Office Administrator | Reveal Email/Phone |
7 | Chairman, ImStem | Reveal Email/Phone |
ImStem Biotechnology Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ImStem Biotechnology?
Imstem Biotechnology, Inc. is a biotechnology company focusing on developing cell therapeutic product derived from human pluripotent stem cells (hESC or iPSC) for tissue repair, treatment of neural, heart, vascular, blood system diseases and autoimmune diseases. With our state-of-art stem cell technologies, we will be able to provide different kinds of therapeutic and research products with unlimited supply and consistent quality in the near future.
keywords:N/AN/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.7M | 21 | -9% | N/A |
#2 | $2.1M | 21 | 5% | N/A |
#3 | $2.1M | 21 | 5% | N/A |
#4 | $2.1M | 21 | -30% | N/A |
#5 | N/A | 21 | -50% | N/A |